BACKGROUND: We sought to examine how expansions in insurance coverage of nonbiologic and biologic disease-modifying antirheumatic drugs affected the access, costs, and health status of older patients with rheumatoid arthritis. METHODS: We identified a nationally representative sample of older adults with rheumatoid arthritis in the 2000-2006 Medicare Current Beneficiary Survey (unweighted n=1051). We examined changes in disease-modifying antirheumatic drug use, self-reported health status, functional status (activities of daily living), and total costs and out-of-pocket costs for medical care and prescription drugs. Tests for time trends were conducted using weighted regressions. RESULTS: Between 2000 and 2006, the proportion of older adults with rheumatoid arthritis who received biologics tripled (4.6% vs 13.2%, P=.01), whereas the proportion of people who used a nonbiologic did not change. During the same period, the proportion of older patients with rheumatoid arthritis rating their health as excellent/good significantly increased (43.0% in 2000 to 55.6% in 2006; P=.015). Significant improvements occurred in activities of daily living measures of functional status. Total prescription drug costs (in 2006 US dollars) increased from $2645 in 2000 to $4685 in 2006, P=.0001, whereas out-of-pocket prescription costs remained constant ($842 in 2000 vs $832 in 2006; P=.68). Total medical costs did not significantly increase ($16,563 in 2000 vs $19,510 in 2006; P=.07). CONCLUSION: Receipt of biologics in older adults with rheumatoid arthritis increased over a period of time when insurance coverage was expanded without increasing patients' out-of-pocket costs. During this time period, concurrent improvements in self-reported health status and functional status suggest improved arthritis care.
BACKGROUND: We sought to examine how expansions in insurance coverage of nonbiologic and biologic disease-modifying antirheumatic drugs affected the access, costs, and health status of older patients with rheumatoid arthritis. METHODS: We identified a nationally representative sample of older adults with rheumatoid arthritis in the 2000-2006 Medicare Current Beneficiary Survey (unweighted n=1051). We examined changes in disease-modifying antirheumatic drug use, self-reported health status, functional status (activities of daily living), and total costs and out-of-pocket costs for medical care and prescription drugs. Tests for time trends were conducted using weighted regressions. RESULTS: Between 2000 and 2006, the proportion of older adults with rheumatoid arthritis who received biologics tripled (4.6% vs 13.2%, P=.01), whereas the proportion of people who used a nonbiologic did not change. During the same period, the proportion of older patients with rheumatoid arthritis rating their health as excellent/good significantly increased (43.0% in 2000 to 55.6% in 2006; P=.015). Significant improvements occurred in activities of daily living measures of functional status. Total prescription drug costs (in 2006 US dollars) increased from $2645 in 2000 to $4685 in 2006, P=.0001, whereas out-of-pocket prescription costs remained constant ($842 in 2000 vs $832 in 2006; P=.68). Total medical costs did not significantly increase ($16,563 in 2000 vs $19,510 in 2006; P=.07). CONCLUSION: Receipt of biologics in older adults with rheumatoid arthritis increased over a period of time when insurance coverage was expanded without increasing patients' out-of-pocket costs. During this time period, concurrent improvements in self-reported health status and functional status suggest improved arthritis care.
Authors: Sebastian Schneeweiss; Amanda R Patrick; Alex Pedan; Laleh Varasteh; Raisa Levin; Nan Liu; William H Shrank Journal: Health Aff (Millwood) Date: 2009-02-03 Impact factor: 6.301
Authors: Beáta J Radovits; Jaap Fransen; Agnes Eijsbouts; Piet L C M van Riel; Roland F J M Laan Journal: Rheumatology (Oxford) Date: 2009-05-28 Impact factor: 7.580
Authors: Wynn G Hunter; Cecilia Z Zhang; Ashley Hesson; J Kelly Davis; Christine Kirby; Lillie D Williamson; Jamison A Barnett; Peter A Ubel Journal: Med Decis Making Date: 2016-01-19 Impact factor: 2.583
Authors: Jeffrey R Curtis; Lang Chen; Aseem Bharat; Elizabeth Delzell; Jeffrey D Greenberg; Leslie Harrold; Joel Kremer; Soko Setoguchi; Daniel H Solomon; Fenglong Xie; Huifeng Yun Journal: Arthritis Care Res (Hoboken) Date: 2014-12 Impact factor: 4.794
Authors: Gregory D Brown; Wynn G Hunter; Ashley Hesson; J Kelly Davis; Christine Kirby; Jamison A Barnett; Dmytro Byelmac; Peter A Ubel Journal: Psychiatr Serv Date: 2017-03-15 Impact factor: 3.084
Authors: Leslie R Harrold; Becky A Briesacher; Dan Peterson; Ashley Beard; Jeanne Madden; Fang Zhang; Jerry H Gurwitz; Stephen B Soumerai Journal: J Rheumatol Date: 2013-01-15 Impact factor: 4.666